MRPL22 Antibody

What is MRPL22 and what cellular function does it serve?

MRPL22 (mitochondrial ribosomal protein L22) is a 206 amino acid protein that functions as a component of the 39S subunit of mammalian mitochondrial ribosomes (mitoribosomes). It plays a crucial role in protein synthesis within the mitochondrion, working in conjunction with other mitochondrial ribosomal proteins. The protein belongs to the ribosomal protein L22P family and is encoded by a gene located on human chromosome 5 . Functionally, MRPL22 contributes to the unique structure of mitoribosomes, which differ from prokaryotic ribosomes in having a higher protein-to-RNA ratio (approximately 75% protein to rRNA compared to the reversed ratio in prokaryotic ribosomes) . MRPL22 is essential for maintaining proper mitochondrial translation, which ultimately affects cellular energy production and metabolism.

What are the common applications for MRPL22 antibodies in research?

MRPL22 antibodies are primarily utilized in several key research applications:

• Western Blotting (WB): For detecting and quantifying MRPL22 protein levels in denatured protein samples, typically with recommended dilutions of 1:500-1:2000 . This technique allows researchers to evaluate protein expression in different cellular contexts.

• Immunohistochemistry (IHC): For visualizing MRPL22 distribution in tissue sections (both paraffin and frozen sections), with typical working dilutions of 1:50-1:200 . This application helps understand tissue-specific expression patterns.

• Immunofluorescence/Immunocytochemistry (IF/ICC): For cellular localization studies, confirming the mitochondrial localization of MRPL22 .

These applications provide complementary data allowing researchers to build a comprehensive understanding of MRPL22 expression, localization, and function in various biological systems.

What species reactivity can be expected from commercial MRPL22 antibodies?

Based on available data, most commercial MRPL22 antibodies show consistent reactivity with human, mouse, and rat samples . This cross-species reactivity is particularly valuable for comparative studies and validation across different experimental models.

Additionally, predictive analyses suggest potential cross-reactivity with several other species, though these predictions require experimental validation:

• High confidence predictions include: pig, zebrafish, bovine, sheep, rabbit, dog, and chicken

• These predictions are typically based on sequence homology analysis of the immunogen sequences

When working with species beyond the validated ones, researchers should conduct preliminary validation experiments with appropriate positive controls to confirm antibody functionality before proceeding with full experimental setups.

How should MRPL22 antibodies be optimally stored and handled to maintain efficacy?

For optimal performance and longevity of MRPL22 antibodies, follow these evidence-based protocols:

• Storage temperature: Store at -20°C for long-term preservation . Some antibodies may be stored at 4°C for shorter periods .

• Formulation preservation: Most MRPL22 antibodies are supplied in phosphate buffered solutions (pH 7.4) containing stabilizers and 50% glycerol to prevent freeze-thaw damage .

• Aliquoting: Upon receipt, divide the antibody into small single-use aliquots to minimize freeze-thaw cycles, which can significantly degrade antibody performance.

• Shipping conditions: These antibodies are typically shipped with ice packs and should be stored immediately at the recommended temperature upon receipt .

• Stability: When properly stored, MRPL22 antibodies typically maintain reactivity for 12 months, though actual performance should be validated periodically through positive controls .

• Thawing protocol: When removing from storage, thaw antibodies completely at room temperature before use, avoid partial thawing and refreezing.

Proper storage and handling are critical for experimental reproducibility and preventing false negative results due to antibody degradation.

What are the recommended protocols for Western blot detection of MRPL22?

For optimal Western blot detection of MRPL22, the following protocol adaptations are recommended based on technical specifications:

• Sample preparation:

  • Include appropriate protease inhibitors in lysis buffers

  • For mitochondrial proteins like MRPL22, consider using specialized mitochondrial extraction protocols

  • Validate protein concentration before loading using standard methods (Bradford/BCA)

• Gel selection and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution of MRPL22 (calculated MW: 24 kDa)

  • Transfer proteins to PVDF or nitrocellulose membranes using standard protocols

• Antibody dilution and incubation:

  • Primary antibody: Dilute MRPL22 antibody 1:500-1:2000 in blocking buffer

  • Starting recommendation: 1:1000 dilution, then optimize based on signal strength

  • Incubate overnight at 4°C for optimal binding

• Validated cell/tissue samples:

  • Confirmed reactive samples include: Jurkat cells, HepG2 cells, and mouse kidney tissue

  • Always include a positive control from these validated sources

• Band interpretation:

  • Expected molecular weight: 24 kDa

  • Note that observed band size may not always match the calculated size due to post-translational modifications, protein processing, or technical factors

  • If multiple bands appear, additional validation may be required

This protocol should be optimized for specific laboratory conditions and equipment to achieve optimal results.

What controls should be included when working with MRPL22 antibodies?

Rigorous experimental design requires appropriate controls when working with MRPL22 antibodies:

• Positive controls:

  • Use cell lines/tissues with confirmed MRPL22 expression such as Jurkat cells, HepG2 cells, or mouse kidney tissue

  • Recombinant MRPL22 protein can serve as a definitive positive control

• Negative controls:

  • Primary antibody omission: Replace primary antibody with equivalent dilution of non-immune IgG from the same host species (rabbit)

  • MRPL22 knockdown/knockout samples if available (siRNA, CRISPR-edited cells)

  • Tissues/cells known to have minimal MRPL22 expression

• Peptide competition assay:

  • Pre-incubate antibody with purified immunogen peptide before application

  • This should eliminate specific binding and confirm antibody specificity

• Loading controls:

  • For mitochondrial protein analysis, include mitochondrial markers (e.g., TOMM20, COX IV)

  • For whole cell lysates, standard loading controls (β-actin, GAPDH, α-tubulin)

• Cross-validation:

  • When possible, validate findings using antibodies from different sources or targeting different epitopes of MRPL22

These controls help establish antibody specificity and ensure experimental results accurately reflect MRPL22 biology rather than technical artifacts.

How can MRPL22 antibodies be utilized to study mitochondrial ribosome assembly and function?

MRPL22 antibodies can be powerful tools for investigating mitochondrial ribosome dynamics through these advanced approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Use MRPL22 antibodies to immunoprecipitate native protein complexes

  • Analyze co-precipitated proteins to identify interaction partners within the 39S ribosomal subunit

  • Combine with mass spectrometry for unbiased interactome analysis

• Proximity labeling approaches:

  • Generate MRPL22 fusion constructs with BioID or APEX2

  • Use antibodies to validate expression and localization of fusion proteins

  • Map the spatial organization of mitoribosomal assembly factors

• Immunofluorescence co-localization:

  • Combine MRPL22 antibodies with other mitoribosomal markers

  • Quantify co-localization coefficients during various cellular states

  • Track dynamic changes during mitochondrial stress responses

• Pulse-chase experiments:

  • Monitor newly synthesized mitochondrial proteins using metabolic labeling

  • Use MRPL22 antibodies to track ribosome assembly kinetics

  • Correlate with mitochondrial translation rates

• Structure-function studies:

  • Combine with site-directed mutagenesis of MRPL22

  • Use antibodies to confirm expression of mutant proteins

  • Analyze effects on mitoribosome assembly and function

These approaches enable researchers to move beyond simple detection toward mechanistic insights into MRPL22's role in mitochondrial translation and ribosome biogenesis.

What considerations should be taken when analyzing MRPL22 post-translational modifications?

MRPL22 undergoes several post-translational modifications (PTMs) that may affect its function and detection. When studying these PTMs:

• Known modification sites:

  • Phosphorylation at Y68

  • Ubiquitination at K86

  • Additional sites may exist but require further validation

• PTM-specific antibody selection:

  • Standard MRPL22 antibodies may have variable ability to detect modified forms

  • Consider PTM-specific antibodies when available (phospho-Y68, ubiquitin-K86)

  • Modification-insensitive antibodies may be preferred for total protein detection

• Sample preparation considerations:

  • Include phosphatase inhibitors when studying phosphorylation

  • Include deubiquitinase inhibitors when studying ubiquitination

  • Consider enrichment strategies (phosphopeptide enrichment, ubiquitin remnant motif antibodies)

• Band pattern interpretation:

  • Modified MRPL22 may appear as higher molecular weight bands

  • Treatment with phosphatases or deubiquitinating enzymes can confirm PTM identity

  • Multiple bands may represent different modification states

• Functional validation approaches:

  • Correlate PTM levels with functional readouts (mitochondrial translation efficiency)

  • Generate PTM-deficient mutants (Y68F, K86R) for functional studies

  • Use antibodies to monitor PTM dynamics during cellular stress

Careful consideration of these factors will enhance the ability to accurately detect and functionally characterize MRPL22 PTMs in various experimental contexts.

How can discrepancies in observed versus expected molecular weight of MRPL22 be interpreted?

Researchers frequently observe discrepancies between calculated (24 kDa) and actual MRPL22 band sizes in Western blots . These discrepancies can be systematically analyzed:

• Post-translational modifications:

  • Phosphorylation, ubiquitination (at K86), or other PTMs can increase apparent molecular weight

  • Multiple modification states may appear as multiple bands

  • Comparison with PTM-specific antibodies can help identify modified species

• Protein processing:

  • MRPL22 contains a mitochondrial targeting sequence that may be cleaved upon import

  • Mature protein may appear smaller than the calculated full-length protein

  • N-terminal and C-terminal antibodies may detect different bands

• Technical factors:

  • Gel percentage affects migration patterns (higher percentage gels improve resolution of lower MW proteins)

  • Buffer systems and running conditions influence apparent molecular weight

  • Protein conformation may affect migration even in denaturing conditions

• Validation approaches:

  • Run recombinant MRPL22 protein as size standard

  • Compare multiple antibodies targeting different epitopes

  • Use MRPL22 knockdown/knockout samples to confirm band specificity

  • Consider protein isoforms (two transcript variants have been identified)

• Reporting considerations:

  • Clearly document observed MW in publications

  • Note discrepancies from expected size

  • Provide validation evidence for band identity

Understanding these factors helps researchers correctly interpret Western blot results and avoid misidentification of MRPL22-specific signals.

What are the common pitfalls in immunohistochemical detection of MRPL22 and how can they be addressed?

Immunohistochemical (IHC) detection of MRPL22 presents several challenges that can be systematically addressed:

• Fixation artifacts:

  • Overfixation may mask epitopes recognized by MRPL22 antibodies

  • Optimize fixation time (typically 24-48 hours in 10% neutral buffered formalin)

  • Consider testing multiple fixatives for optimal antigen preservation

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval methods are typically necessary

  • Compare citrate buffer (pH 6.0) vs. EDTA buffer (pH 9.0)

  • Optimize retrieval time and temperature based on tissue type

• Background reduction strategies:

  • Mitochondrial proteins may show high background due to abundant distribution

  • Block endogenous peroxidase activity thoroughly (3% H₂O₂, 10-15 minutes)

  • Extend protein blocking step (5% normal serum, 1 hour at room temperature)

  • Include 0.1-0.3% Triton X-100 for improved antibody penetration

• Dilution optimization:

  • Start with recommended dilution range (1:50-1:200)

  • Perform titration experiments on known positive tissues

  • Extend primary antibody incubation time (overnight at 4°C)

• Detection system selection:

  • For low abundance, use high-sensitivity detection systems (polymer-based)

  • Avoid excessive amplification that may increase background

• Validated control tissues:

  • Human liver cancer tissue has been validated for MRPL22 IHC

  • Include tissue microarrays for multi-tissue validation when possible

• Counterstaining considerations:

  • Use light hematoxylin counterstaining to avoid obscuring specific signals

  • Consider dual-labeling with mitochondrial markers to confirm localization

These optimizations should be systematically implemented with appropriate controls to achieve specific and reproducible MRPL22 detection in tissue samples.

How can cross-reactivity be assessed when using MRPL22 antibodies in non-validated species?

When extending MRPL22 antibody applications to species beyond the validated ones (human, mouse, rat), researchers should follow this systematic validation approach:

• Sequence homology analysis:

  • Compare MRPL22 amino acid sequences between validated and target species

  • Focus on the immunogen region used to generate the antibody

  • High sequence conservation (>80%) suggests potential cross-reactivity

• Preliminary Western blot validation:

  • Run samples from both validated and target species

  • Include positive and negative controls

  • Compare band patterns and intensities

  • Verify specificity through knockdown experiments if possible

• Epitope mapping considerations:

  • If epitope sequence is known, perform in silico analysis of conservation

  • Consider antibodies raised against conserved regions for cross-species applications

  • Multiple antibodies targeting different epitopes provide stronger validation

• Tissue-specific expression patterns:

  • Compare IHC/IF patterns between species in tissues with expected expression

  • Verify subcellular localization (mitochondrial for MRPL22)

  • Consistency in expression patterns supports antibody specificity

• Functional validation:

  • Correlate protein detection with functional readouts (e.g., mitochondrial translation)

  • Verify that antibody detects changes in protein levels after relevant interventions

• Calibration experiment design:

  • Use increasing protein loads to establish detection limits

  • Compare sensitivity between validated and target species

  • Adjust antibody concentrations accordingly

This systematic approach increases confidence in antibody performance across species and reduces the risk of misinterpreting experimental results.

What strategies can address weak or inconsistent MRPL22 signal in Western blot applications?

When encountering weak or inconsistent MRPL22 signals in Western blot experiments, consider these methodological optimizations:

• Sample preparation enhancements:

  • Optimize lysis buffers for mitochondrial proteins (consider specialized mitochondrial extraction)

  • Include fresh protease/phosphatase inhibitors

  • Avoid excessive sample heating which may cause protein degradation

  • Increase protein loading (start with 30-50 µg total protein)

• Transfer optimization:

  • For 24 kDa proteins like MRPL22, use higher methanol concentrations in transfer buffer (15-20%)

  • Optimize transfer time (typically 60-90 minutes for proteins of this size)

  • Consider semi-dry transfer systems for efficient transfer of smaller proteins

• Antibody incubation modifications:

  • Increase primary antibody concentration (start at 1:500 if using 1:2000)

  • Extend incubation time (overnight at 4°C)

  • Use 5% BSA instead of milk for blocking and antibody dilution

  • Include 0.05% Tween-20 in antibody dilution buffer to reduce background

• Signal enhancement strategies:

  • Use high-sensitivity ECL substrates

  • Consider alternative detection methods (fluorescent secondary antibodies)

  • Longer exposure times, being careful to avoid overexposure

  • Signal enhancement systems (biotin-streptavidin)

• Membrane optimization:

  • PVDF membranes may provide better protein retention than nitrocellulose

  • Activate PVDF with methanol before use

  • Consider low-fluorescence PVDF for fluorescent detection systems

• Verified positive control inclusion:

  • Use samples known to express MRPL22 (Jurkat, HepG2, mouse kidney)

  • Include recombinant MRPL22 protein as reference standard

Systematic implementation of these optimizations should improve detection sensitivity while maintaining specificity for MRPL22 protein.

How can MRPL22 antibodies contribute to research on mitochondrial dysfunction in disease models?

MRPL22 antibodies offer valuable tools for investigating mitochondrial dysfunction across various disease contexts:

• Neurodegenerative disorders:

  • Monitor MRPL22 levels in Alzheimer's, Parkinson's, and ALS models

  • Correlate with mitochondrial translation efficiency

  • Assess relationship between mitoribosome integrity and disease progression

  • Examine potential compensatory changes in mitoribosomal proteins

• Cancer metabolism studies:

  • Compare MRPL22 expression between normal and cancer tissues

  • Evaluate correlation with metabolic reprogramming

  • Assess impact of oncogenic signaling on mitoribosome composition

  • Identify potential vulnerabilities in cancer-specific mitochondrial translation

• Aging research:

  • Track age-related changes in MRPL22 expression and post-translational modifications

  • Correlate with mitochondrial protein synthesis decline

  • Evaluate interventions targeting mitochondrial translation

• Mitochondrial disease models:

  • Assess compensatory responses in mitoribosomal components

  • Evaluate therapeutic responses to mitochondrial-targeted interventions

  • Develop biomarkers for mitochondrial translation defects

• Methodological approaches:

  • Tissue microarrays for high-throughput screening across disease types

  • Multi-label immunofluorescence to assess relationships with other mitochondrial parameters

  • Automated image analysis for quantitative assessment of expression patterns

  • Integration with functional mitochondrial assays (oxygen consumption, mitochondrial protein synthesis)

These applications leverage MRPL22 antibodies as tools to understand fundamental aspects of mitochondrial biology in disease states and potential therapeutic approaches.

What considerations are important when using MRPL22 antibodies in combination with other mitochondrial markers?

Multiplexed detection approaches combining MRPL22 with other mitochondrial markers require careful experimental design:

• Marker selection strategy:

  • Combine MRPL22 with markers for different mitochondrial compartments:

    • Outer membrane: TOMM20, VDAC

    • Inner membrane: TIM23, Complex subunits

    • Matrix: HSP60, TFAM

  • Choose markers that answer specific biological questions about mitoribosome localization and dynamics

• Antibody compatibility considerations:

  • Select primary antibodies raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential immunostaining with complete stripping between rounds

  • Validate each antibody individually before multiplexing

• Signal separation methods:

  • For fluorescent detection, ensure adequate spectral separation between fluorophores

  • For brightfield IHC, use distinguishable chromogens

  • Consider signal amplification for low-abundance targets

• Colocalization analysis:

  • Use appropriate quantitative methods (Manders' coefficient, Pearson's correlation)

  • Employ super-resolution microscopy for detailed colocalization studies

  • Analyze changes in colocalization patterns under different conditions

• Controls for multiplexed detection:

  • Single-stained samples for each marker to establish baseline patterns

  • Secondary-only controls to assess non-specific binding

  • Blocking peptide controls to confirm specificity

• Functional correlation:

  • Combine with functional assays (e.g., mitochondrial protein synthesis)

  • Correlate spatial relationships with functional parameters

  • Use genetic manipulations to validate functional relationships

These considerations enable powerful multiplexed analyses that reveal spatial and functional relationships between MRPL22 and other mitochondrial components.

How can MRPL22 antibodies be integrated into high-throughput or automated screening approaches?

MRPL22 antibodies can be effectively incorporated into high-throughput screening platforms through these methodological adaptations:

• Microplate-based assays:

  • Optimize antibody concentrations for 96/384-well format detection

  • Develop in-cell Western protocols for rapid screening

  • Establish automated immunofluorescence workflows

  • Create robust positive controls and standard curves for quantification

• Tissue microarray applications:

  • Validate antibody performance on tissue microarrays containing diverse samples

  • Optimize staining protocols for consistent results across multiple tissues

  • Implement digital pathology approaches for automated scoring

  • Correlate with clinical parameters and outcomes

• Flow cytometry adaptation:

  • Optimize permeabilization protocols for mitochondrial protein detection

  • Combine with mitochondrial dyes for multiparameter analysis

  • Establish compensation controls for multiplexed detection

  • Consider imaging flow cytometry for spatial information

• Automated microscopy considerations:

  • Develop reliable autofocus algorithms for mitochondrial structures

  • Implement machine learning approaches for pattern recognition

  • Establish quantitative parameters (intensity, distribution patterns)

  • Design multi-position acquisition protocols for statistical power

• Quality control parameters:

  • Determine Z-factor for assay robustness

  • Implement positive and negative controls on each plate

  • Establish acceptance criteria for assay performance

  • Monitor batch effects across plates and experimental days

• Data analysis pipelines:

  • Develop automated image analysis workflows

  • Create standardized reporting formats

  • Implement machine learning for complex pattern recognition

  • Design database structures for results integration with other parameters

These adaptations enable MRPL22 antibodies to serve as valuable tools in large-scale screening efforts investigating mitochondrial biology across numerous experimental conditions.

What are the most appropriate positive and negative controls for validating MRPL22 antibody specificity?

Comprehensive validation of MRPL22 antibody specificity requires strategic selection of controls:

• Positive controls:

  • Cell/tissue types with confirmed high expression:

    • Jurkat cells, HepG2 cells, mouse kidney tissue

    • Tissues with high mitochondrial content (heart, liver)

  • Recombinant MRPL22 protein expressed in bacterial or mammalian systems

  • Overexpression systems (transfected cells with MRPL22 expression constructs)

• Negative controls:

  • Genetic validation approaches:

    • MRPL22 knockdown using validated siRNA/shRNA

    • CRISPR/Cas9-mediated knockout cell lines

    • MRPL22-null tissues (if available from conditional knockout models)

  • Technical controls:

    • Primary antibody omission

    • Isotype control antibody at equivalent concentration

    • Pre-immune serum from host species

• Specificity validation methods:

  • Immunizing peptide competition assay:

    • Pre-incubate antibody with excess immunizing peptide

    • Should abolish specific signal while non-specific binding remains

  • Multiple antibody validation:

    • Compare staining patterns using antibodies targeting different MRPL22 epitopes

    • Consistent patterns across antibodies support specificity

• Cross-species validation:

  • Compare detection patterns across species with known sequence homology

  • Consistent results in evolutionary conserved regions support specificity

• Reporting standards:

  • Document all validation approaches in publications

  • Include representative images of controls

  • Describe specific details of control experiments (concentrations, incubation times)

  • Specify lot numbers of antibodies used

These comprehensive validation approaches provide crucial evidence for antibody specificity and experimental reproducibility.

How should researchers interpret variations in MRPL22 expression across different cell types and tissues?

When analyzing differential MRPL22 expression patterns, consider these interpretive frameworks:

• Correlation with mitochondrial content:

  • Compare MRPL22 levels with established mitochondrial mass markers (TOMM20, citrate synthase)

  • Determine if MRPL22 expression simply tracks with mitochondrial abundance or shows tissue-specific regulation

  • Normalize to mitochondrial markers when comparing across tissues

• Relationship to metabolic profiles:

  • Assess whether MRPL22 expression correlates with oxidative phosphorylation capacity

  • Compare glycolytic versus oxidative tissues/cells

  • Evaluate whether expression changes track with metabolic switching

• Developmental and cell-state considerations:

  • Analyze expression during cellular differentiation

  • Compare proliferating versus quiescent cells

  • Assess relationship to mitochondrial biogenesis programs

• Quantification approaches:

  • Use multiple methodologies (Western blot, IHC, qPCR)

  • Employ appropriate normalization strategies

  • Consider absolute quantification methods for cross-sample comparison

• Subcellular distribution analysis:

  • Evaluate whether MRPL22 shows uniform mitochondrial distribution

  • Assess potential cytosolic pools or non-mitochondrial localization

  • Examine co-localization with mitoribosome assembly markers

• Response to interventions:

  • Analyze changes with mitochondrial stress

  • Evaluate effects of metabolic interventions

  • Compare with other mitoribosomal proteins to identify coordinated regulation

This multifaceted interpretation framework allows researchers to distinguish biologically meaningful variation from technical artifacts and develop hypotheses about MRPL22's role in tissue-specific mitochondrial function.

What statistical approaches are recommended for quantifying and comparing MRPL22 expression across experimental conditions?

Robust statistical analysis of MRPL22 expression data requires application of appropriate methods:

• Western blot quantification:

  • Perform densitometry using linear range of detection

  • Normalize to appropriate loading controls (mitochondrial and global)

  • Use technical replicates to assess measurement variability

  • Apply log transformation for ratio-based comparisons

  • Report fold-change with confidence intervals

• Immunohistochemistry quantification:

  • Establish scoring system (H-score, Allred score, or digital quantification)

  • Blind observers to experimental conditions

  • Use multiple fields/regions per sample

  • Apply appropriate transformations for non-normally distributed data

  • Consider hierarchical statistical models for nested experimental designs

• Sample size determination:

  • Conduct power analysis based on pilot data

  • Account for biological and technical variability

  • Consider effect size of biological significance

  • Report sample size justification in methods

• Statistical test selection:

  • For normally distributed data: t-tests (paired/unpaired) or ANOVA with appropriate post-hoc tests

  • For non-parametric data: Mann-Whitney, Kruskal-Wallis tests

  • For repeated measures: RM-ANOVA or mixed models

  • For correlation analysis: Pearson or Spearman based on data distribution

• Multiple comparison correction:

  • Apply appropriate methods (Bonferroni, Benjamini-Hochberg)

  • Report both raw and adjusted p-values

  • Balance Type I and Type II error risks

• Visualization recommendations:

  • Show individual data points rather than only means/errors

  • Use box plots or violin plots to display distribution

  • Include clear indication of sample size

  • Represent biological and technical replicates distinctly

These statistical approaches enhance reproducibility and allow meaningful interpretation of MRPL22 expression changes across experimental conditions.

What emerging technologies might enhance the utility of MRPL22 antibodies in mitochondrial research?

Several cutting-edge technologies promise to expand MRPL22 antibody applications:

• Proximity labeling approaches:

  • BioID or APEX2 fusion with MRPL22 for identifying spatial neighbors

  • TurboID for rapid labeling kinetics to capture dynamic interactions

  • Split-BioID systems to investigate conditional interactions

  • Integration with mass spectrometry for unbiased proximity mapping

• Super-resolution microscopy:

  • STED, PALM, or STORM imaging for sub-mitochondrial localization

  • Live-cell super-resolution with compatible antibody fragments

  • Correlative light and electron microscopy (CLEM) for ultrastructural context

  • Expansion microscopy for physical magnification of structures

• Spatial transcriptomics integration:

  • Combine antibody detection with in situ RNA visualization

  • Correlate protein levels with local transcriptional activity

  • Investigate spatial heterogeneity of mitochondrial translation

• Single-cell proteomics:

  • Mass cytometry (CyTOF) with metal-conjugated antibodies

  • Microfluidic-based single-cell Western blotting

  • Integration with single-cell transcriptomics for multi-omic analysis

  • Spatial proteomics for subcellular resolution

• Intrabody development:

  • Engineer antibody fragments for live-cell applications

  • Develop conformation-specific intrabodies to track structural changes

  • Create optogenetic-intrabody fusions for controlled perturbation

• Cryo-electron tomography integration:

  • Immunogold labeling for precise localization

  • Correlative approaches to map MRPL22 within mitoribosome structure

  • In situ structural biology of native complexes